Workflow
TOP Financial (TOP)
icon
Search documents
TOP RANKED ROSEN LAW FIRM Encourages Vera Bradley, Inc. Investors to Inquire About Securities Class Action Investigation – VRA
GlobeNewswire News Room· 2025-07-27 14:32
Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Vera Bradley, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Vera Bradley securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Financial Performance and Market Reaction - On June 11, 2025, Vera Bradley announced disappointing financial results for the first quarter of the 2026 fiscal year, leading to a 19% drop in stock price on the same day [3]. - The CEO of Vera Bradley acknowledged that top line and profitability trends had continued to decline over several quarters [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].
ROSEN, A TOP RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT
GlobeNewswire News Room· 2025-07-22 19:49
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by August 11, 2025, acting on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for the number of securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Rocket Pharmaceuticals made misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing serious adverse events, including participant deaths [5]. - It is claimed that these misleading statements led to artificially inflated prices for Rocket Pharmaceuticals securities, resulting in investor damages when the true information became public [5].
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
Prnewswire· 2025-07-22 17:01
Core Insights - IDEAYA Biosciences and Jiangsu Hengrui Pharmaceuticals announced an oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer, focusing on its efficacy and safety in small-cell lung cancer (SCLC) patients [1][3] - IDE849 is a potential first-in-class DLL3-targeting Topoisomerase-1 (TOP1) payload antibody drug conjugate (ADC), addressing significant unmet medical needs in various solid tumors [1][3] Group 1: Presentation Details - The oral presentation will take place on September 7, 2025, from 4:45-6:00 PM (CET) and will cover a Phase 1 study of SHR-4849 (IDE849) in relapsed SCLC [4] - A poster presentation will also be held on September 8, 2025, discussing the combination mechanism and pre-clinical synergy data between TOP1-payload based ADCs and IDE161, a proprietary PARG inhibitor [2][5] Group 2: Clinical Development - The Phase 1 trial for IDE849 is ongoing in China, with data from over 70 SCLC patients expected to be presented, including results from dose escalation and multiple expansion doses [6] - The U.S. Phase 1 trial of IDE849 in SCLC patients was initiated in the third quarter of 2025 [6] Group 3: Company Strategy - IDEAYA aims to evaluate rational combinations of therapies to improve clinical outcomes for cancer patients, including the use of IDE849 as a monotherapy and in combination with immunotherapy and IDE161 [2][3] - The company has a robust pipeline focused on synthetic lethality and ADCs, including bispecifics, to address unmet medical needs in cancer [7]
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DDD
GlobeNewswire News Room· 2025-07-20 13:32
Group 1 - The Rosen Law Firm is reminding investors who purchased 3D Systems Corporation securities between August 13, 2024, and May 12, 2025, of the August 12, 2025, lead plaintiff deadline for a class action lawsuit [1][2] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [2][5] Group 2 - The lawsuit alleges that during the class period, 3D Systems made false and misleading statements regarding its business resilience and the impact of weakened customer spending [4] - It is claimed that the updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [4] - The lawsuit asserts that these misleading public statements resulted in investor damages when the true information became public [4] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in this area [3]
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHVN
GlobeNewswire News Room· 2025-07-20 12:34
Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Biohaven Ltd. securities, alleging misleading statements regarding the company's drug regulatory prospects and clinical efficacy during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Biohaven Ltd. securities purchased between March 24, 2023, and May 14, 2025 [1]. - Allegations include that Biohaven overstated the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which could negatively impact the company's business and financial condition [5]. Group 2: Participation Information - Investors who purchased Biohaven securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Centene Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CNC
GlobeNewswire News Room· 2025-07-18 21:35
Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Centene Corporation securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its financial performance [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Centene common stock between December 12, 2024, and June 30, 2025, and aims to provide compensation without out-of-pocket fees through a contingency fee arrangement [2][5]. - The lawsuit alleges that Centene's management provided materially false and misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, highlighting the Rosen Law Firm's achievements in this area, including significant settlements and recognition in the legal community [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone, showcasing its capability in handling such cases [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, meaning investors are not represented unless they retain counsel, and participation as a lead plaintiff is not necessary for potential recovery [7].
ROSEN, A TOP-RANKED LAW FIRM, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG
GlobeNewswire News Room· 2025-07-18 18:03
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased PepGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
GlobeNewswire News Room· 2025-07-17 19:29
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sarepta Therapeutics, Inc. securities between June 22, 2023, and June 24, 2025, of the upcoming lead plaintiff deadline on August 25, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Sarepta made false and misleading statements regarding its gene therapy product, ELEVIDYS, which posed significant safety risks and failed to detect severe side effects during trials [5]. - The adverse events related to ELEVIDYS treatment led to a halt in recruitment and dosing in trials, attracting regulatory scrutiny and increasing risks around the therapy's approvals [5].
CROWN HOLDINGS RECOGNIZED BY FORBES AS THE TOP PACKAGING COMPANY ON TRACK TO ACHIEVE NET-ZERO CARBON EMISSIONS
Prnewswire· 2025-07-17 13:00
Core Insights - Crown Holdings, Inc. has been recognized by Forbes as the top packaging company on track to achieve net-zero carbon emissions, ranking 22nd overall among 200 evaluated companies [1][2] Group 1: Recognition and Achievements - Crown's recognition as a Net Zero Leader for 2025 highlights the dedication of its global team towards sustainability goals [2] - The company ranked 22nd in emissions projections, risk management, financial strength, governance, and organizational preparedness [1] Group 2: Sustainability Initiatives - Crown's Twentyby30™ initiative, established in 2020, serves as a roadmap for achieving its net zero target, focusing on emissions reductions, water preservation, recycling, and ethical sourcing [3] - The company emphasizes that sustainability is central to its business, fostering innovation and progress in reducing its carbon footprint [4] Group 3: Reporting and Transparency - Crown's 2024 Sustainability Report titled "Built to Last" provides measurable data on its sustainability progress and highlights environmental and social goals that have been achieved or surpassed [4]
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG
GlobeNewswire News Room· 2025-07-15 17:03
Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The class action lawsuit has been filed against PepGen Inc. for misleading statements regarding the effectiveness and safety of its drug PGN-EDO51 and the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4]. - The deadline to move the Court to serve as lead plaintiff is August 8, 2025 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overall commercial prospects of the drug [4]. - The misleading public statements led to investor damages when the true information became known [4].